"Vasoconstrictor Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs used to cause constriction of the blood vessels.
| Descriptor ID |
D014662
|
| MeSH Number(s) |
D27.505.954.411.793
|
| Concept/Terms |
Vasoconstrictor Agents- Vasoconstrictor Agents
- Agents, Vasoconstrictor
- Vasoconstrictor Drugs
- Drugs, Vasoconstrictor
- Vasoconstrictors
- Vasoactive Agonists
- Agonists, Vasoactive
- Vasopressor Agents
- Agents, Vasopressor
|
Below are MeSH descriptors whose meaning is more general than "Vasoconstrictor Agents".
Below are MeSH descriptors whose meaning is more specific than "Vasoconstrictor Agents".
This graph shows the total number of publications written about "Vasoconstrictor Agents" by people in this website by year, and whether "Vasoconstrictor Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 2 | 0 | 2 |
| 1997 | 0 | 1 | 1 |
| 1998 | 1 | 0 | 1 |
| 1999 | 2 | 1 | 3 |
| 2001 | 0 | 2 | 2 |
| 2003 | 0 | 1 | 1 |
| 2004 | 2 | 1 | 3 |
| 2005 | 2 | 2 | 4 |
| 2006 | 2 | 3 | 5 |
| 2007 | 1 | 1 | 2 |
| 2008 | 0 | 2 | 2 |
| 2009 | 0 | 2 | 2 |
| 2010 | 3 | 2 | 5 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 1 | 2 |
| 2015 | 3 | 1 | 4 |
| 2016 | 2 | 4 | 6 |
| 2017 | 2 | 1 | 3 |
| 2018 | 3 | 2 | 5 |
| 2019 | 4 | 4 | 8 |
| 2020 | 4 | 6 | 10 |
| 2021 | 1 | 3 | 4 |
| 2022 | 0 | 4 | 4 |
| 2023 | 0 | 5 | 5 |
| 2024 | 2 | 0 | 2 |
| 2025 | 5 | 3 | 8 |
To return to the timeline,
click here.
Below are the most recent publications written about "Vasoconstrictor Agents" by people in Profiles.
-
Cardiac Arrest Pharmacopeia: A Personalized Approach to Drug Administration During Cardiopulmonary Resuscitation. Crit Care Clin. 2026 Jan; 42(1):149-168.
-
The Association Between Vasopressin and Adverse Kidney Outcomes in Children and Young Adults Requiring Vasopressors on Continuous Renal Replacement Therapy. Crit Care Explor. 2024 10; 6(10):e1156.
-
Physiological Mechanisms of Hypertension and Cardiovascular Disease in End-Stage Kidney Disease. Curr Hypertens Rep. 2022 10; 24(10):413-424.
-
Surgical Infection Society Research Priorities: A Narrative Review of Fourteen Years of Progress. Surg Infect (Larchmt). 2021 Jun; 22(5):568-582.
-
Perspective of the Surviving Sepsis Campaign on the Management of Pediatric Sepsis in the Era of Coronavirus Disease 2019. Pediatr Crit Care Med. 2020 11; 21(11):e1031-e1037.
-
Fluid Response Evaluation in Sepsis Hypotension and Shock: A Randomized Clinical Trial. Chest. 2020 10; 158(4):1431-1445.
-
Executive Summary: Surviving Sepsis Campaign International Guidelines for the Management of Septic Shock and Sepsis-Associated Organ Dysfunction in Children. Pediatr Crit Care Med. 2020 02; 21(2):186-195.
-
Surviving Sepsis Campaign International Guidelines for the Management of Septic Shock and Sepsis-Associated Organ Dysfunction in Children. Pediatr Crit Care Med. 2020 02; 21(2):e52-e106.
-
Concurrent Use of Calcium Chloride and Arginine Vasopressin Infusions in Pediatric Patients with Acute Cardiocirculatory Failure. Pediatr Cardiol. 2019 Jun; 40(5):1046-1056.
-
Twik-2-/- mouse demonstrates pulmonary vascular heterogeneity in intracellular pathways for vasocontractility. Physiol Rep. 2019 01; 7(1):e13950.